Daniel D. Adams

Dan Adams is Executive Chairman and Global Head of Business Development of Protein Sciences Corporation, a leader in developing and manufacturing vaccines, therapeutics and diagnostics using its patented baculovirus expression vector system. Dan became CEO in 1996 of the then failed company. He recruited a top management team that has progressed two vaccines through late-stage clinical trials. The lead vaccine, Flublok, a patented, first in class recombinant influenza vaccine, received licensure from FDA in January 2013. Under the new leadership, the Company focused on intellectual property and now has broad protection for its BEVS insect cell platform technology, an ideal platform for manufacturing new vaccines, and a pipeline of proprietary products. Prior to surrendering the CEO’s role to the long time Chief Operating Officer in 2010, Dan guided the Company to becoming soldily profitable and cash flow positive

Dan founded and served as CEO of a venture capital fund. He made the first outside equity investment in Genentech and helped build the company in its initial stages. Under his management, he was with the New York law firm of Sullivan & Cromwell. He also was a company commander with the U.S. Army in Southeast Asia during the Vietnam